Covaxin booster dose study shows promising results
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The drug is priced at Rs 2000 for a course of 40 tablets
The transaction is expected to close in the first quarter of 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Hitz shall assume new role from January 17th, 2022
Subscribe To Our Newsletter & Stay Updated